• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Delphinus appoints Mark J. Forchette president and CEO

Delphinus appoints Mark J. Forchette president and CEO

September 18, 2014
CenterWatch Staff

Delphinus Medical Technologies, a Michigan developer of SoftVue, a whole breast ultrasound system that incorporates a ring transducer design, has named Mark J. Forchette president and CEO.

Previously, Forchette was president and CEO of OptiMedica, an ophthalmic medical device company. He led the start-up venture through development and growth, successfully completed multiple rounds of financing and oversaw the company’s acquisition by Abbott Laboratories in 2013. He began his career in the medtech industry as a sales representative at Greishaber, where he became vice president of U.S. sales and marketing and led the company through its acquisition by Alcon.

Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a circular transducer technology to transmit and receive ultrasound signals. SoftVue captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast, something no other currently available ultrasound system can do. With a short scan time of one to two minutes per breast, SoftVue presents a complete image map of the whole breast, providing a consistent and uniform exam without reliance on operator skill and technique.

In recent years, it has become understood that dense breast tissue can obscure breast cancer, rendering mammography ineffective for 40% of women in the U.S. With growing state legislation requiring women to be notified of their breast tissue density, new non-radiation imaging solutions are needed for the health professionals engaged every day in bettering breast health.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing